Independent Growth & AI Strategy Brief · PointClickCare

You've won skilled nursing. The next growth curve is delivery, not building.

PointClickCare already sits under ~60% of U.S. SNF beds and the largest LTPAC dataset in North America. The 2025 HLTH repositioning and the Advisor AI suite are the right bets. The binding constraint on the next $1B of value isn't the roadmap — it's getting AI adopted and monetized across 30,000+ under-staffed provider orgs. That is a Product Delivery & Growth problem.

Prepared by Ankit Kohli For the VP, Product Delivery & Growth — AI conversation July 2026 Independent analysis · not affiliated with PointClickCare

An outside read built from public sources. Figures marked est. are third-party or analyst estimates, not company-audited numbers; sections 4–6 are my strategic assessment, labeled as such. Sources linked at the end.

01

The situation, in one read

PointClickCare is not a company looking for product-market fit — it's a category-defining incumbent looking for its second act. New-logo runway in skilled nursing is largely spent. The growth math now runs through net revenue retention: attaching the AI Advisor suite, analytics, and RCM into an installed base that's already captive — and expanding upward into the acute-to-post-acute seam and the payer side of the network.

Every one of those moves succeeds or dies at the same chokepoint: can a chronically short-staffed, low-tech-maturity facility actually adopt what ships, fast enough to renew and expand? Build velocity is no longer the differentiator. Delivery-and-adoption velocity is.

30,000+
provider organizations on platform
company-stated
~60%
of the U.S. SNF EHR segment
analyst est.
700M+
network patient visits
company-stated
Every
major U.S. health plan on the network
company-stated
400+
marketplace integration partners
company-stated
02

Why the timing is unusually good

The staffing crisis is the wedge

Chronic labor shortages make documentation-burden and workflow automation a survival purchase, not a nice-to-have — precisely what the Advisor AI suite (Chart, Referral, Billing) is built to relieve.

Value-based care raises the payoff of data

SNF Value-Based Purchasing adds staffing-turnover, infection, and total-nurse-staffing measures scored from FY2026. Quality now has a direct dollar consequence — and PCC owns the measurement layer.

Interoperability mandates favor the network

TEFCA and CMS data-exchange rules reward whoever already sits between acute, post-acute, and payers. The Audacious Inquiry and Collective Medical assets make PCC that connective tissue.

Thin operator margins reward ROI tools

Revenue capture (Billing Advisor) and readmission reduction (Predictive Return to Hospital) pay for themselves — an easier internal sell than software that only adds cost.

The non-obvious one

CMS repealed the federal minimum nurse-staffing mandate in December 2025. Most vendors will read this as pure upside for operator margins. It's double-edged: it removes one compliance-driven reason to buy staffing software. The lesson for delivery & growth — the durable wedge is hard ROI (revenue, readmissions), not compliance theater. Pricing and packaging the Advisor suite around dollars-returned insulates the expansion motion from regulatory whiplash.

03

Where the moat holds — and where it doesn't

Defensible

  • SNF dominance: 9 of the 10 largest U.S. skilled-nursing chains are customers (analyst-reported) — switching costs are brutal.
  • The data + payer network: the largest LTPAC dataset plus every major health plan is a moat rivals can't buy their way into quickly.
  • Absorbed a rival: acquiring American HealthTech (Jan 2024) removed a competitor and pulled its base onto the platform.
  • M&A muscle: Collective Medical + Audacious Inquiry built the acute↔post-acute bridge by acquisition, fast.

Exposed

  • Senior living is a real contest: Yardi, Eldermark, and MatrixCare are entrenched — hence the 2025/26 next-gen platform rebuild. Here PCC is challenger, not incumbent.
  • Home health / hospice breadth favors WellSky and MatrixCare (ResMed-backed).
  • Incumbency backlash: ~60% share invites antitrust framing and price resentment from captive customers — an adoption-goodwill risk every time a new module is attached.
  • Payer-provider channel conflict: serving both sides can make providers wary of who sees their data.
04

Six growth vectors, ranked by near-term leverage

My read on where the delivery-and-growth org should concentrate. Ordered by how much revenue is reachable without a new sales motion.

1 · Installed-base cross-sell & attach

HIGHEST LEVERAGE

The whole Advisor suite is an attach engine. 30,000+ orgs already run the EHR; landing Referral, Billing, and Chart Advisor into existing accounts is far cheaper than new-logo and is the fastest path to net revenue retention.

Why nowAdvisor Suite is live and shipping as discrete, ROI-justified SKUs (Billing Advisor launched Jun 2026).
Exec riskModule fatigue and pricing-power backlash from captive customers — adoption must precede the upsell, not follow it.
Near-term leverageNRR / expansionPrice backlash

2 · AI documentation, risk & staffing

CORE

Attack the #1 operator pain directly — documentation burden and staffing. The suite that clinicians actually adopt becomes the renewal anchor for everything else.

Why nowAdvisor AI is shipping into a market desperate for labor relief.
Exec riskClinician trust and AI accuracy/liability in a regulated setting; shelfware is the failure mode.
Adoption-ledClinical trust

3 · Data & analytics products

UPSIDE

Monetize the 700M-visit dataset via benchmarking and payer-facing risk products. The data is most valuable to the plans already on the network.

Why nowValue-based care + MA growth make LTPAC data commercially valuable.
Exec riskData governance, consent, and provider wariness of data being resold.
High-marginData governance

4 · Acute-to-post-acute & payer expansion

STRATEGIC

Own the hospital→SNF transition and sell to health plans, not just facilities. The HLTH 2025 rebrand explicitly stakes this "nexus" position.

Why nowPredictive Return to Hospital already sells to plans; discharge volume is rising.
Exec riskSelling to hospitals/payers is a longer, more contested motion than PCC's SNF-native muscle.
New TAMNew sales motion

5 · Marketplace / platform play

COMPOUNDING

Turn 400+ integration partners into a true LTPAC app-store — rev-share plus deepening lock-in as the platform of record.

Why nowEcosystem exists; clean APIs convert it into a channel.
Exec riskSustained developer investment; payoff is slower than attach.
Lock-inSlower payoff

6 · Senior living re-entry

DEFENSIVE

The next-gen Senior Living platform (2026) is a contest to win, not a base to defend. Land-and-expand against entrenched niche players.

Why nowNew platform is commercially available in 2026.
Exec riskYardi / Eldermark / MatrixCare are incumbents here — PCC must displace, not default-win.
ChallengerDisplacement cost
05

The three problems this role actually owns

A VP of Product Delivery & Growth — AI lives in the seam between what ships and what it earns. Strip away the title and it's three hard problems. Here's how I'd attack each.

Time-to-value & adoption at scale

With 30,000+ orgs, two next-gen platform rebuilds, and a new AI suite all landing at once, the bottleneck isn't building — it's getting understaffed, low-tech-maturity facilities to adopt and realize value fast. Slow adoption silently kills every expansion number downstream.

How I'd attack itInstrument time-to-first-value as the north-star delivery metric, not launch date. Segment the base by tech-maturity and route white-glove vs. self-serve accordingly. Treat onboarding as a product with its own funnel — because an unadopted module is negative revenue once you count the support load.

Converting the installed base into expansion revenue

New-logo runway in SNF is thin. Growth depends on attach and net revenue retention — landing Advisor, analytics, and RCM into existing accounts without triggering the price backlash that ~60% share invites.

How I'd attack itPackage on dollars-returned, not features — lead expansion conversations with a facility's own realized ROI (captured revenue, avoided readmissions). Sequence attach by proven adoption so the upsell rides trust already earned. This is the muscle I've run for years in a different vertical: turning an existing relationship and hard numbers into the next contract.

Shipping AI clinicians actually adopt

Documentation and predictive AI only create value if frontline staff trust and use it. The delivery-and-growth challenge is embedding AI into real workflows — intake, charting, billing — with measurable ROI, in a regulated, liability-sensitive, short-staffed setting. Shelfware is the default failure.

How I'd attack itShip AI where it removes a keystroke, not where it demos well — embed it in the existing workflow rather than a new screen. Gate rollout on measured trust and accuracy, publish the ROI back to the facility, and let adoption data — not the roadmap — decide what scales. Building AI systems people actually run is the specific thing I do.
Why I built this

I'm not sending a resume. I'm showing you the work.

I'm a growth and commercial operator — cross-border payments & FX, M&A and corporate development, transformation — and my edge is that I ship AI systems that compress weeks of knowledge work into an afternoon. I'm not claiming to know LTPAC better than you do. I'm showing you the three things this role turns on, and that I already operate the way it demands.

Adoption at scale

Getting complex products used by non-technical operators — my whole career has been driving adoption where the user is busy and skeptical.

Expansion revenue

Turning an existing relationship plus hard numbers into the next contract — the exact attach/NRR motion, run in payments and advisory.

AI that ships

I build working AI systems, not decks about them. This brief — research, analysis, and page — was produced with my own.

The meta-point: this entire brief — the sourcing, the competitive read, the growth-vector scoring, and this page — was assembled with an AI research-and-build system I run. What took a strategy team three weeks is an afternoon. That's the delivery-and-growth leverage I'd bring in-house on day one.
Ankit Kohli
Growth & commercial operator · builds AI systems that ship
Start a conversation →
Sources & reliability notes

Independent analysis prepared by Ankit Kohli for discussion purposes. Not affiliated with, endorsed by, or representing PointClickCare. Company-stated figures are attributed as such; items marked est. are third-party or analyst estimates and are directional, not audited. Sections 3–5 reflect the author's strategic assessment.